Printer Friendly

MBI ANNOUNCES LAUNCH OF ALBUNEX(R) IN JAPAN

 SAN DIEGO, Nov. 30 /PRNewswire/ -- Molecular Biosystems Inc. (NYSE: MB) (MBI) today announced that Shionogi & Co. Ltd., MBI's licensee in Japan, initiated marketing of Albunex(R), MBI's ultrasound contrast agent. This product launch follows the establishment of a National Health Insurance (NHI) price for Albunex(R). Prices for ethical drugs marketed in Japan are determined by NHI rates. On Nov. 26, 1993, the Chuikyo, the Central Social Insurance Medical Council in Japan, established an NHI rate of 8,129 yen, or approximately $75.00, per 5 ml vial of Albunex(R). It is estimated that, on the average, two vials will be used per procedure.
 Under MBI's agreement with Shionogi, MBI will manufacture Albunex(R) and Shionogi will market and distribute the product. MBI will receive 30 percent of the NHI price as a transfer price for product shipped to Shionogi. Shionogi is Japan's fifth largest pharmaceutical company, with the largest sales and distribution network in that country.
 Albunex(R) will be used in Japan during echocardiography (ultrasound imaging of the heart) to enhance the identification of precise endocardial borders and to assess blood flow within the cardiac chambers, both of which are used to measure the efficiency of the main pumping chamber of the heart and to assess damage to the heart. Albunex(R) is the first commercially available ultrasound contrast imaging agent in Japan. No such agents are yet available in the United States. additional approval applications for Albunex(R) are currently pending in the United States, the United Kingdom and a few other European countries.
 Molecular Biosystems Inc., based in San Diego, is a leader in the development of contrast agents for medical imaging, including ultrasound, MRI and CT. Once approved, its flagship product, Albunex(R), will be marketed and distributed worldwide by MBI's partners, including Mallinckrodt Medical Inc. (IMCERA Group, NYSE: IMA) in the United States, Shionogi & Co., Ltd. in Japan and Hafslund Nycomed (NYSE: HN) in Europe.
 -0- 11/30/93
 /CONTACT: Sherry L. Mesman, VP-finance and CFO of Molecular Biosystems, 619-452-0681, ext. 2212/
 (MB)


CO: Molecular Biosystems Inc.; Shionogi & Co. Ltd. ST: California IN: MTC SU:

NY-LM -- SD001 -- 8589 11/30/93 09:09 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 30, 1993
Words:361
Previous Article:WEIRTON STEEL CORPORATION ISSUES STATEMENT
Next Article:AVIRON RAISES $15 MILLION IN PRIVATE FINANCING -- NEW BIOPHARMACEUTICAL COMPANY FOCUSED ON PREVENTION
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters